JP2007510622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510622A5 JP2007510622A5 JP2006534362A JP2006534362A JP2007510622A5 JP 2007510622 A5 JP2007510622 A5 JP 2007510622A5 JP 2006534362 A JP2006534362 A JP 2006534362A JP 2006534362 A JP2006534362 A JP 2006534362A JP 2007510622 A5 JP2007510622 A5 JP 2007510622A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- gene
- chain gene
- vie
- vib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 238000000034 method Methods 0.000 claims 13
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 10
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 9
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 9
- 108091023037 Aptamer Proteins 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 108091008875 B cell receptors Proteins 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50947303P | 2003-10-08 | 2003-10-08 | |
| PCT/US2004/033176 WO2005034733A2 (en) | 2003-10-08 | 2004-10-08 | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007510622A JP2007510622A (ja) | 2007-04-26 |
| JP2007510622A5 true JP2007510622A5 (enExample) | 2007-11-22 |
Family
ID=34434984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534362A Pending JP2007510622A (ja) | 2003-10-08 | 2004-10-08 | Ｂ細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8119340B2 (enExample) |
| EP (1) | EP1678195A4 (enExample) |
| JP (1) | JP2007510622A (enExample) |
| AU (1) | AU2004279441B2 (enExample) |
| CA (1) | CA2541360A1 (enExample) |
| WO (1) | WO2005034733A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CA2541360A1 (en) | 2003-10-08 | 2005-04-21 | Bradley T. Messmer | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| US20070105165A1 (en) * | 2005-11-04 | 2007-05-10 | Charles Goolsby | Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers |
| US7767206B2 (en) * | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー／エス | Ｈｅｒ２エピトープに対するモノクローナル抗体 |
| WO2011147986A1 (en) * | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
| AU2011261396B2 (en) | 2010-06-02 | 2015-11-05 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| CN103796677B (zh) | 2011-04-20 | 2019-08-16 | 健玛保 | 针对her2和cd3的双特异性抗体 |
| KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| DE102012212025A1 (de) * | 2012-07-10 | 2014-01-16 | Osram Gmbh | Leuchtmodul |
| EP2741084B1 (en) | 2012-12-07 | 2020-01-22 | AVA Lifescience GmbH | Method of prognosing the clinical course of chronic lymphocytic leukemia (CLL) |
| EP2948469A4 (en) | 2013-01-23 | 2016-11-02 | Univ Leland Stanford Junior | STABILIZED HEPATITIS B CORE POLYPEPTIDE |
| EP3508502B1 (en) | 2013-09-20 | 2023-04-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
| EP3149167B1 (en) * | 2014-05-30 | 2019-09-04 | Academia Sinica | Aptamer targeting mage-a3 peptide and uses thereof |
| EP3328994A4 (en) | 2015-07-31 | 2019-04-17 | Memorial Sloan-Kettering Cancer Center | CD56-Faced Antigen-Binding Proteins and Uses Thereof |
| EP3341004A4 (en) * | 2015-08-24 | 2019-05-15 | Medimmune, LLC | MRKA POLYPEPTIDES, ANTIBODIES AND USES THEREOF |
| US10221249B2 (en) | 2015-09-10 | 2019-03-05 | Affigen, Llc | Method of making patient specific anti-idiotype antibodies |
| AU2018221172A1 (en) * | 2017-02-17 | 2019-09-05 | Adimab, Llc | Monoclonal antibodies and cocktails for treatment of Ebola infections |
| MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
| AU2018277824A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
| CN109752548B (zh) * | 2019-02-01 | 2022-05-06 | 广州金域医学检验中心有限公司 | 评估慢性淋巴细胞白血病预后的组合试剂及系统 |
| US12378321B2 (en) | 2019-03-08 | 2025-08-05 | Memorial Sloan Kettering Cancer Center | ADAM17 binding molecules and uses thereof |
| US20220306750A1 (en) * | 2019-08-12 | 2022-09-29 | City Of Hope | Il1rap antibodies |
| CN113461818B (zh) * | 2021-06-30 | 2022-01-21 | 徐州医科大学 | 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法 |
| WO2023172890A2 (en) * | 2022-03-07 | 2023-09-14 | Agenus Inc. | Anti-ilt2 antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP2270049A3 (en) * | 2002-04-12 | 2011-03-09 | Medimmune, Inc. | Recombinant anti-interleukin-9-antibody |
| CA2541360A1 (en) | 2003-10-08 | 2005-04-21 | Bradley T. Messmer | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
-
2004
- 2004-10-08 CA CA002541360A patent/CA2541360A1/en not_active Abandoned
- 2004-10-08 US US10/575,671 patent/US8119340B2/en active Active
- 2004-10-08 AU AU2004279441A patent/AU2004279441B2/en not_active Ceased
- 2004-10-08 WO PCT/US2004/033176 patent/WO2005034733A2/en not_active Ceased
- 2004-10-08 EP EP04794503A patent/EP1678195A4/en not_active Withdrawn
- 2004-10-08 JP JP2006534362A patent/JP2007510622A/ja active Pending
-
2012
- 2012-01-20 US US13/354,774 patent/US9745364B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007510622A5 (enExample) | ||
| Ozdemirli et al. | Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy | |
| Li et al. | Diffuse large B-cell lymphoma | |
| Grisaru-Tal et al. | Metastasis-entrained eosinophils enhance lymphocyte-mediated antitumor immunity | |
| Sarkadi et al. | Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system | |
| Ghia et al. | Ordering of human bone marrow B lymphocyte precursors by single-cell polymerase chain reaction analyses of the rearrangement status of the immunoglobulin H and L chain gene loci | |
| Ghia et al. | Chronic lymphocytic leukemia | |
| Safarzadeh Kozani et al. | In like a lamb; out like a lion: marching CAR T cells toward enhanced efficacy in B-ALL | |
| JP2010531140A5 (enExample) | ||
| HRP20221041T1 (hr) | Anti-pd-1 antitijela i sastavi | |
| Tjandra et al. | Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis | |
| Kamata et al. | Increased frequency of surface IgA-positive plasma cells in the intestinal lamina propria and decreased IgA excretion in hyper IgA (HIGA) mice, a murine model of IgA nephropathy with hyperserum IgA | |
| JP2009539841A5 (enExample) | ||
| CN111148514A (zh) | 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂 | |
| JP2009521909A5 (enExample) | ||
| JP2007510622A (ja) | Ｂ細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 | |
| Freria et al. | Serial systemic injections of endotoxin (LPS) elicit neuroprotective spinal cord microglia through IL-1-dependent cross talk with endothelial cells | |
| Wen et al. | Association of B-1 B cells with follicular dendritic cells in spleen | |
| Xiang et al. | ROS-activated CXCR2+ neutrophils recruited by CXCL1 delay denervated skeletal muscle atrophy and undergo P53-mediated apoptosis | |
| Ikezumi et al. | The role of lymphocytes in the experimental progressive glomerulonephritis | |
| JP2008538173A5 (enExample) | ||
| İşman et al. | Association between SDF1-3′ A or CXCR4 gene polymorphisms with predisposition to and clinicopathological characteristics of prostate cancer with or without metastases | |
| JP2008522162A5 (enExample) | ||
| Naito et al. | RORγt is dispensable for the development of intestinal mucosal T cells | |
| Nündel et al. | The role of Bruton's tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells |